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Abstract 
Carbohydrate antigen 19-9 (CA 19-9) is a sensitive marker for pancreatic and 
hepatobiliary malignancies. The highest frequency of elevated serum CA 19-9 levels is 
found among patients with pancreatic cancer. CA 19-9 has recently been demonstrated 
to be a marker of digestive tract malignancies. We report the case of a patient with a 
gastric cancer and a very high serum CA 19-9 level. During laparotomy, a large mass was 
found in the antrum. A distal gastrectomy with D2 dissection of the lymph nodes was 
performed. Histological examination, including immunohistochemistry, revealed an 
adenocarcinoma of the stomach producing CA 19-9. To the best of our knowledge, no 
patient with an extremely high serum CA 19-9 level resulting from a gastric 
adenocarcinoma has been reported previously. 
Introduction 
Carbohydrate antigen 19-9 (CA 19-9) has recently been developed of digestive tract 
malignancies. The CA 19-9 antibody has been obtained by immunizing mice with human 
colorectal cell line [1]. The tumor marker CA 19-9 is a sensitive marker for pancreatic and 
hepatobiliary malignacies [2]. The highest frequency of elevated serum CA 19-9 level is 
found in patients with pancreatic cancer. Occasionally reported in other primary 
neoplasms, it is most often associated with the gastrointestinal tract [3]. To the best of our 
knowledge, no patient with an extremely high serum CA 19-9 level resulting from a 
gastric adenocarcinoma has been reported previously.  
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Case Report 
A 76-year-old man presented with right upper abdominal pain and loss of appetite. On admission, 
laboratory findings for white and red blood cells and platelet count were normal; the biochemical 
parameters were also within normal limits. The serum level of carcinoembryonic antigen was 3.3 ng/ml 
(cut-off 5.0 ng/ml), and the serum level of CA 19-9 was extremely high at 7,080 U/ml (cut-off 37 U/ml). 
Upper gastrointestinal barium study revealed a 7.0 cm filling defect in the antrum. Abdominal 
computed tomography scan showed a 5 × 6 cm tumor occupying the antrum and no liver metastasis. 
Gastroendoscopic examination revealed a large tumor on the antrum. Multiple biopsies showed 
moderately differentiated tubular adenocarcinoma of the stomach. During laparotomy, no ascites, 
evidence of enlargement, liver metastasis or peritoneal dissemination of the cancer was observed. The 
tumor was removed by sharp dissection and a distal gastrectomy with D2 lymph node dissection was 
performed (fig. 1). Pathological review of the resected specimen showed a poorly differentiated 
non-solid-type adenocarcinoma of the stomach with positive lymph node metastasis for all lymph nodes 
(21/21 lymph nodes) (fig. 2a). The resected specimen was evaluated as Borrmann type III, stage IIIB 
(pT3, pN2, pM0). Immunohistochemical study showed that CA 19-9-positive cells were present in the 
tumor (fig. 2b) and in the resected lymph nodes (fig. 2c, d). The patient was treated with 4 courses of 
systematic chemotherapy with CDDP and TS-1. The serum CA 19-9 level decreased to 4,070 ng/ml 
2 months after surgery. Eight months later, ascites in the abdominal cavity was observed on an 
abdominal computed tomography image. The serum CA 19-9 level had increased to 120,000 ng/ml. The 
patient died from peritonitis carcinomatosa 8 months after the initial admission. 
Discussion 
CA 19-9 has been used in the diagnosis of digestive tract malignancies. The serum 
CA 19-9 concentration increases to the greatest extent in patients with pancreatic cancer 
or cholangiocarcinoma. CA 19-9 resembles carcinoembryonic antigen in colorectal 
carcinoma and various different gastrointestinal adenocarcinomas [2]. The expression of 
CA 19-9 has been studied in normal and malignant gastrointestinal tissues. The antigen 
was found by immunoperoxidase staining in 40–80% of carcinomas from the gallbladder, 
stomach, pancreas, and colon [3]. The association of elevated CA 19-9 levels with gastric 
carcinoma has been presented in a case report and in other studies. Elevated serum levels 
of CA 19-9 have been described in 15–30% of patients with gastric cancers, but these 
patients had multiple liver metastases. Elevated CA 19-9 levels have been significantly 
correlated with lymph node metastasis, vascular invasion and liver metastasis [4]. Our 
patient had an exceptionally elevated CA 19-9 level, with a serum level over 7,000 ng/ml, 
and a stomach cancer without liver metastasis or peritoneal dissemination as determined 
by laparotomy; at the time of death, the patient’s serum CA 19-9 was over 120,000 ng/ml. 
A high serum CA 19-9 level in a patient with gastric cancer is extremely rare [5]. 
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Fig. 1. Resected specimen, 6.0 × 5.0 cm in diameter. 
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Fig. 2. Photomicrographs of the stomach (hematoxylin and eosin stain). a Lower-power (original 
magnification ×100) view of the gastric cancer. b Immunohistochemical staining for CA 19-9 in the 
area of the adenocarcinoma (×100). c Photomicrograph of a resected lymph node (×40) showing 
metastasis of the gastric cancer. d Immunohistochemical staining for CA 19-9 in the lymph node of the 
adenocarcinoma patient (×40). 
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